Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07409493

IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols

The goal of this clinical trial is to compare two ovarian stimulation protocols used in in vitro fertilization (IVF): the fixed Progestin-Primed Ovarian Stimulation (PPOS) protocol and the GnRH Antagonist protocol. The study will evaluate IVF outcomes and embryo development patterns using time-lapse embryo monitoring technology. The main questions the study aims to answer are:

* Does the fixed - PPOS protocol achieve similar numbers of mature eggs, good-quality embryos, and clinical outcomes compared to the GnRH Antagonist protocol? * Are there differences in embryo development patterns (morphokinetics) between the two protocols when monitored by time-lapse imaging? * How does embryo quality (KIDScore) compare between the two protocols?

Study Design:

Researchers will randomly assign 148 women undergoing IVF to two groups:

* PPOS group (n=74): Will receive FSH injections (oral Duphaston 20mg daily) starting from day 2-3 of the menstrual cycle * GnRH Antagonist group (n=74): Will receive FSH injections (Orgalutran 0.25mg injections) when follicles reach ≥14mm

Participants will:

* Undergo controlled ovarian stimulation with their assigned protocol for approximately 10-12 days * Have regular ultrasound monitoring and blood tests to track follicle development * Undergo egg retrieval procedure when follicles are mature * Have all embryos cultured in the EmbryoScope time-lapse incubator with continuous monitoring * Have embryos frozen on Day 5/6 for future transfer

Study Location:

Department of Assisted Reproduction and Andrology, Hanoi Obstetrics and Gynecology Hospital

Study Duration: January 2026 - June 2028

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Hanoi Obstetrics and Gynecology Hospital

Hanoi, 100000, Vietnam

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women aged 20-45 years
  • Indicated for in vitro fertilization (IVF) treatment
  • Planned freeze-all embryo strategy
  • Voluntary participation in research.

Exclusion criteria

  • Systemic diseases
  • Use of hormonal medications within 3 months prior to enrollment
  • Oocyte donation cycles
  • Unwilling or unable to participate in research

Treatment and study plan

Progestin-Primed Ovarian Stimulation

Drug

Ovarian stimulation using progestin-primed ovarian stimulation (PPOS) protocol. Patients receive recombinant FSH starting from day 2-3 of menstrual cycle, concomitantly with oral Dydrogesterone 20mg daily to prevent premature LH surge. All embryos are cultured using time-lapse technology and cryopreserved for subsequent frozen embryo transfer.

Antagonist protocol for IVF

Drug

Ovarian stimulation using GnRH antagonist protocol. Patients receive recombinant FSH starting from day 2-3 of menstrual cycle. GnRH antagonist is added when leading follicle reaches 12-14mm diameter to prevent premature LH surge. All embryos are cultured using time-lapse technology and cryopreserved for subsequent frozen embryo transfer.

Primary outcomes

  1. Blastocyst formation rate

    Time frame: Day 5 to Day 6 after oocyte retrieval

    Number of high-quality blastocysts (grade ≥ 3BB) obtained per cycle

Secondary outcomes

  1. Embryo morphokinetic development

    Time frame: Day 2 to day 5 after oocyte retrieval

    Compare the embryomorphokinetic milestones evaluated using the time-lapse evaluation system (EmbryoScope+ Vitrolife).

Study contacts

Contact information is provided by the study sponsor or research team.

Thanh Huy Dao, MD

CONTACT

[email protected]

+84 971597096

Sponsors and collaborators

Lead sponsor

Hanoi Medical University

Other

Collaborators

  • Hanoi Obstetrics and Gynecology Hospital

Registry information

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Feb 13, 2026
Registry last updated
Feb 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.